The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.

about

Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer Testosterone monitoring for men with advanced prostate cancer: Review of current practices and a survey of Canadian physicians.

P2860

Q29994552-8CFF3529-9ED1-4DC9-9BA7-E648A34FBBF7 Q33803812-0DA4B024-A99E-4FAD-8355-1E49FBD9C30E

P2860

The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.

Item

http://www.wikidata.org/entity/Q53798282

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh-hant

name

The prognostic impact of serum ...... r and the SRD5A2 polymorphism.

@en

The prognostic impact of serum ...... r and the SRD5A2 polymorphism.

@nl

type

Item

label

The prognostic impact of serum ...... r and the SRD5A2 polymorphism.

@en

The prognostic impact of serum ...... r and the SRD5A2 polymorphism.

@nl

prefLabel

The prognostic impact of serum ...... r and the SRD5A2 polymorphism.

@en

The prognostic impact of serum ...... r and the SRD5A2 polymorphism.

@nl

P1476

The prognostic impact of serum ...... r and the SRD5A2 polymorphism.

@en

P2093

A Takeuchi

http://www.w3.org/2001/XMLSchema#string

A Yokomizo

http://www.w3.org/2001/XMLSchema#string

E Kashiwagi

http://www.w3.org/2001/XMLSchema#string

J Inokuchi

http://www.w3.org/2001/XMLSchema#string

K Kiyoshima

http://www.w3.org/2001/XMLSchema#string

K Tatsugami

http://www.w3.org/2001/XMLSchema#string

M Eto

http://www.w3.org/2001/XMLSchema#string

N Fujimoto

http://www.w3.org/2001/XMLSchema#string

T Dejima

http://www.w3.org/2001/XMLSchema#string

P2860

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.

Cancer statistics, 2012

Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults

Targeted androgen pathway suppression in localized prostate cancer: a pilot study.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.

Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT

High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients.

Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database

Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

P2888

pcan.2016.2

P304

191-196

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/PCAN.2016.2

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Masaki Shiota

P577

2016-02-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1036890576

http://www.w3.org/2001/XMLSchema#string

P698

26857022

http://www.w3.org/2001/XMLSchema#string

The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.

about

P2860

P2860

The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698